Plus Therapeutics, Inc. announced the formation of a Scientific Advisory Board (SAB) with the appointment of leading experts in the fields of neuro-oncology, preclinical drug development, and nanotechnology. The SAB will guide and advise the Company as it advances its proprietary and versatile nanotechnology platform developing innovative chemotherapeutics and radiotherapeutics for rare cancers that address unmet medical needs. Founding members of the SAB include: Andrew Brenner, M.D., Ph.D. – Dr. Brenner is a medical oncologist and tumor biologist with a focus in drug development for the management of primary brain tumors and breast neoplasms. His interests are in developing novel therapeutics for the treatment of malignancy with a focus on overcoming resistance to conventional therapeutics. This experience includes navigation of regulatory processes including IND enabling studies, authoring study protocols, coordinating multicenter studies, as well as acting as principal investigator of 14 industry and investigator-initiated Phase 1 trials since 2008. John McKew, Ph.D. – Dr. McKew has 27 years of experience developing novel therapeutics where he successfully advanced therapies through preclinical and into clinical development. He is currently Chief Operating Officer of Lumos Pharma. Prior to Lumos Pharma, Dr. McKew was Vice President of Research at aTyr Pharma where he led a research team discovering and advancing protein-based therapeutics for rare diseases. He has also served as Acting Scientific Director for the National Center for Advancing Translational Science (NCATS) intramural group, a part of the National Institute of Health (NIH). At NCATS, his lab’s work on rare diseases and public/private partnerships led to the collaborative advancement of several therapeutic candidates currently being commercialized by pharmaceutical companies. Vladimir P. Torchilin, Ph.D., D.Sc. – Dr. Torchilin is a University Distinguished Professor and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. He obtained a M.S. in Chemistry as well as a Ph.D. and D.Sc. in Polymer Chemistry and Chemistry of Physiologically Active Compounds from Moscow University. In 1991, Dr. Torchilin joined MGH/Harvard Medical School as the Head of Chemistry Program, Center for Imaging and Pharmaceutical Research, and Associate Professor of Radiology. Since 1998 Dr. Torchilin has been with Northeastern University, including as the Chair of the Department of Pharmaceutical Sciences from 1998-2008. His research interests include liposomes, lipid-core micelles, biomedical polymers, drug delivery and targeting, pharmaceutical nanocarriers, experimental cancer immunology.